Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
3D-Qsar and Docking Studies on Adenosine A2a Receptor Antagonists by the Comfa Method Publisher Pubmed



Pourbasheer E1 ; Shokouhi Tabar S1 ; Masand VH2 ; Aalizadeh R3 ; Ganjali MR4, 5
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Chemistry, Payame Noor University (PNU), Tehran, Iran
  2. 2. Department of Chemistry, Vidya Bharati College, Camp, Amravati, Maharashtra, India
  3. 3. Laboratory of Analytical Chemistry, Department of Chemistry, National and Kapodistrian University of Athens, Athens, Greece
  4. 4. Center of Excellence in Electrochemistry, University of Tehran, Tehran, Iran
  5. 5. Biosensor Research Center, Endocrinology & Metabolism Research Center, Tehran University of Medical Sciences, Tehran, Iran

Source: SAR and QSAR in Environmental Research Published:2015


Abstract

Parkinson’s disease affects millions of people around the world. Recently, adenosine A2A receptor antagonists have been identified as a drug target for the treatment of Parkinson’s disease. Consequently, there is an immediate need to develop new classes of A2A receptor antagonists. In the present analysis, three-dimensional quantitative structure–activity relationship (3D-QSAR) studies were performed on a series of pyrimidines, using comparative molecular field analysis (CoMFA). The best prediction was obtained with a CoMFA standard model (q2 = 0.475, r2 = 0.977) and a CoMFA region focusing model (q2 = 0.637, r2 = 0.976) combined with steric and electrostatic fields. The structural insights derived from the contour maps helped to better interpret the structure–activity relationships. Also, to understand the structure–activity correlation of A2A receptor antagonists, we have carried out molecular docking analysis. Based on the results obtained from the present 3D-QSAR and docking studies, we have identified some key features for increasing the activity of compounds, which have been used to design new A2A receptor antagonists. The newly designed molecules showed high activity with the obtained models. © 2015 Taylor & Francis.